Enzon Pharmaceuticals, Inc. entered into the Eighth Amendment to its Section 382 Rights Agreement on February 27, 2026, extending the Final Expiration Date from noon, New York City time, on March 2, 2026, to noon, New York City time, on March 11, 2026. This marks the eighth amendment to the Rights Agreement since its original date of August 14, 2020, with previous extensions occurring on June 2, 2021, May 16, 2024, March 31, 2025, August 13, 2025, September 30, 2025, December 23, 2025, and January 30, 2026. The company also issued a press release on February 27, 2026, announcing an extension to the expiration date for its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock for shares of Enzon's common stock. After this extension, the exchange offer is set to expire one minute after 11:59 p.m., Eastern time, on March 9, 2026, unless further extended. These actions are undertaken in connection with a proposed merger between Enzon and Viskase Companies, Inc., for which Enzon has filed a registration statement on Form S-4 with the SEC.